Statins and their interactions with other lipid-modifying medications: Safety issues in the elderly

Therapeutic Advances in Drug Safety

Volumn 3, Issue 1, 2012, Pages 35-46

  Ho, Clement K M ^a   Walker, Simon W ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

adverse effects; bile acid sequestrants; drug drug interactions; elderly; ezetimibe; fibrates; fish oil; nicotinic acid; statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BILE ACID SEQUESTRANT; DOCOSAHEXAENOIC ACID; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LAROPIPRANT; MEVALONIC ACID; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID ESTER; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FLUSHING; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; MYALGIA; MYOPATHY; NEOPLASM; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME;

EID: 84859055200     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098611428486     Document Type: Review

References (75)

1. Afilalo J. Duque G. Steele R. Jukema J.W. de Craen A.J. Eisenberg M.J. (2008) Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol 51: 37–45.
2. Backman J.T. Kyrklund C. Kivisto K.T. Wang J.S. Neuvonen P.J. (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68: 122–129.
3. Bader T. (2010) The myth of statin-induced hepatotoxicity. Am J Gastroenterol 105: 978–980.
4. Ballantyne C.M. Davidson M.H. McKenney J. Keller L.H. Bajorunas D.R. Karas R.H. (2008) Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 101: 1428–1436.
5. Bays H.E. McKenney J. Maki K.C. Doyle R.T. Carter R.N. Stein E. (2010) Effects of prescription omega-3-acid ethyl esters on non–high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 85: 122–128.
6. Bellosta S. Paoletti R. Corsini A. (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(23 Suppl. 1): III50–III57.
7. Chalasani N. (2005) Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 41: 690–695.
8. Chalasani N. Gorski J.C. Patel N.H. Hall S.D. Galinsky R.E. (2001) Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 34: 1103–1108.
9. Cohen D.E. Anania F.A. Chalasani N. (2006) An assessment of statin safety by hepatologists. Am J Cardiol 97(8A): 77C–81C.
10. Corsini A. Bellosta S. Baetta R. Fumagalli R. Paoletti R. Bernini F. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84: 413–428.
11. Davidson M.H. Stein E.A. Bays H.E. Maki K.C. Doyle R.T. Shalwitz R.A. (2007) Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29: 1354–1367.
12. Deedwania P. Stone P.H. Bairey Merz C.N. Cosin-Aguilar J. Koylan N. Luo D. (2007) Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115: 700–707.
13. Delahoy P. Magliano D.J. Webb K. Grobler M. Liew D. (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Therapeut 31: 236–244.
14. DeWilde S. Carey I.M. Bremner S.A. Richards N. Hilton S.R. Cook D.G. (2003) Evolution of statin prescribing 1994–2001: a case of agism but not of sexism? Heart 89: 417–421.
15. Di Spirito M. Morelli G. Doyle R.T. Johnson J. McKenney J. (2008) Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Expert Opin Pharmacother 9: 2939–2945.
16. Durrington P.N. Bhatnagar D. Mackness M.I. Morgan J. Julier K. Khan M.A. (2001) An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 85: 544–548.
17. Eckel R.H. (2010) Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 95: 2015–2022.
18. Empson M. Flood V. Ma G. Eastman C.J. Mitchell P. (2007) Prevalence of thyroid disease in an older Australian population. Intern Med J 37: 448–455.
19. Fazio S. (2008) Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clin Ther 30: 294–306.
20. Food and Drug Administration (2011) FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm.
21. George J. Byth K. Farrell G.C. (1995) Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 50: 727–730.
22. Golomb B.A. Evans M.A. (2008) Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8: 373–418.
23. Gosai P. Liu J. Doyle R.T. Johnson J. Carter R. Sica D. (2008) Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. Expert Opin Pharmacother 9: 2947–2953.
24. Gotto A.M. Jr (2007) Statin therapy and the elderly: SAGE advice? Circulation 115: 681–683.
25. Graham D.J. Staffa J.A. Shatin D. Andrade S.E. Schech S.D. La Grenade L. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. Jama 292: 2585–2590.
26. Grundy S.M. Vega G.L. McGovern M.E. Tulloch B.R. Kendall D.M. Fitz-Patrick D. (2002) Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162: 1568–1576.
27. Guyton J.R. Goldberg A.C. Kreisberg R.A. Sprecher D.L. Superko H.R. O–Connor C.M. (1998) Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 82: 737–743.
28. Harris W.S. Ginsberg H.N. Arunakul N. Shachter N.S. Windsor S.L. Adams M. (1997) Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 4: 385–391.
29. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.
30. Hunt D. Young P. Simes J. Hague W. Mann S. Owensby D. (2001) Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 134: 931–940.
31. Jacobson T.A. (2006) Overcoming ‘ageism– bias in the treatment of hypercholesterolaemia: a review of safety issues with statins in the elderly. Drug Saf 29: 421–448.
32. Jones P.H. Davidson M.H. (2005) Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95: 120–122.
33. Joy T.R. Hegele R.A. (2009) Narrative review: statin-related myopathy. Ann Intern Med 150: 858–868.
34. Karas R.H. Kashyap M.L. Knopp R.H. Keller L.H. Bajorunas D.R. Davidson M.H. (2008) Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 8: 69–81.
35. Kennerfalk A. Ruigomez A. Wallander M.A. Wilhelmsen L. Johansson S. (2002) Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother 36: 797–803.
36. Knopp R.H. Alagona P. Davidson M. Goldberg A.C. Kafonek S.D. Kashyap M. (1998) Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47: 1097–1104.
37. Ko D.T. Mamdani M. Alter D.A. (2004) Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. Jama 291: 1864–1870.
38. Kosoglou T. Statkevich P. Johnson-Levonas A.O. Paolini J.F. Bergman A.J. Alton K.B. (2005) Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44: 467–494.
39. Kyrklund C. Backman J.T. Kivisto K.T. Neuvonen M. Laitila J. Neuvonen P.J. (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69: 340–345.
40. Kyrklund C. Backman J.T. Neuvonen M. Neuvonen P.J. (2003) Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73: 538–544.
41. Lewis S.J. Moye L.A. Sacks F.M. Johnstone D.E. Timmis G. Mitchell J. (1998) Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 129: 681–689.
42. Lindeman R.D. Tobin J. Shock N.W. (1985) Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33: 278–285.
43. Lipka L. Sager P. Strony J. Yang B. Suresh R. Veltri E. (2004) Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 21: 1025–1032.
44. Martin P.D. Warwick M.J. Dane A.L. Hill S.J. Giles P.B. Phillips P.J. (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25: 2822–2835.
45. McCormack P.L. Keating G.M. (2005) Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 65: 2719–2740.
46. McKenney J. (2003) Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm 60: 995–1005.
47. McKenney J. Bays H. Koren M. Ballantyne C.M. Paolini J.F. Mitchel Y. (2010) Safety of extended-release niacin/laropiprant in patients with dyslipidemia. J Clin Lipidol 4: 105–112 e101.
48. McKenney J.M. Jones P.H. Bays H.E. Knopp R.H. Kashyap M.L. Ruoff G.E. (2007) Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192: 432–437.
49. McKenney J.M. Swearingen D. Di Spirito M. Doyle R. Pantaleon C. Kling D. (2006) Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 46: 785–791.
50. McLean A.J. Le Couteur D.G. (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56: 163–184.
51. Medicines and Healthcare Products Regulatory Agency (2010) Simvastatin: increased risk of myopathy at high dose (80 mg). Drug Safety Update 3(10): 7–8.
52. Miettinen T.A. Pyorala K. Olsson A.G. Musliner T.A. Cook T.J. Faergeman O. (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 96: 4211–4218.
53. Miller D.B. Spence J.D. (1998) Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34: 155–162.
54. Nair K. (2005) Aging muscle. Am J Clin Nutr 81: 953–963.
55. National Institute for Health and Clinical Excellence (2010) Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guideline 67, National Institute for Health and Clinical Excellence.
56. Newman C. Tsai J. Szarek M. Luo D. Gibson E. (2006) Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97: 61–67.
57. Parkinson A. Mudra D.R. Johnson C. Dwyer A. Carroll K.M. (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199: 193–209.
58. Pasternak R.C. Smith S.C. Jr Bairey-Merz C.N. Grundy S.M. Cleeman J.I. Lenfant C. (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40: 567–572.
59. Patrick J.E. Kosoglou T. Stauber K.L. Alton K.B. Maxwell S.E. Zhu Y. (2002) Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 30: 430–437.
60. Perry C.M. (2009) Extended-release niacin (nicotinic acid)/laropiprant. Drugs 69: 1665–1679.
61. Prueksaritanont T. Tang C. Qiu Y. Mu L. Subramanian R. Lin J.H. (2002) Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30: 1280–1287.
62. Reid F.D. Cook D.G. Whincup P.H. (2002) Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 88: 15–19.
63. Sathasivam S. Lecky B. (2008) Statin induced myopathy. Bmj 337: a2286.
64. Shepherd J. Blauw G.J. Murphy M.B. Bollen E.L. Buckley B.M. Cobbe S.M. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623–1630.
65. Staels B. Dallongeville J. Auwerx J. Schoonjans K. Leitersdorf E. Fruchart J.C. (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088–2093.
66. Steinhagen-Thiessen E. Hilz H. (1976) The age-dependent decrease in creatine kinase and aldolase activities in human striated muscle is not caused by an accumulation of faulty proteins. Mech Ageing Dev 5: 447–457.
67. Tandra S. Vuppalanchi R. (2009) Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 11: 272–278.
68. Tavazzi L. Maggioni A.P. Marchioli R. Barlera S. Franzosi M.G. Latini R. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372: 1223–1230.
69. Taylor A.J. Sullenberger L.E. Lee H.J. Lee J.K. Grace K.A. (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double- blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512–3517.
70. Thompson P.D. Clarkson P. Karas R.H. (2003) Statin-associated myopathy. Jama 289: 1681–1690.
71. Tolman K.G. (2002) The liver and lovastatin. Am J Cardiol 89: 1374–1380.
72. Weltman M.D. Farrell G.C. Hall P. Ingelman-Sundberg M. Liddle C. (1998) Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27: 128–133.
73. White C.M. (2002) A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 42: 963–970.
74. Williams D. Feely J. (2002) Pharmacokinetic–pharmacodynamic drug interactions with HMG-CoA reducatsae inhibitors. Clin Pharmacokinet 41: 343–370.
75. Xydakis A.M. Ballantyne C.M. (2002) Combination therapy for combined dyslipidemia. Am J Cardiol 90(10B): 21K–29K.